Compare Appian Corp (APPN) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs GSK plc — how do they compare? Appian Corp trades at $34.26 (market cap $2.54B), while GSK plc trades at $50.1 (market cap $102.60B). The key difference: GSK plc is far larger — about 40.4× Appian Corp's market cap, and GSK plc pays a 3.57% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | GSK | |
|---|---|---|
Market Cap | $2.54B | $102.60B |
Sector | Technology | Health |
52-Week High | $45.64 | $61.18 |
52-Week Low | $18.72 | $38.22 |
Enterprise Value | $2.67B | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian Corporation (APPN) trades at $35.05, down 1.49% on the day, following a series of recent earnings beats. The stock exhibits a bullish technical trend with strong moving average support, though oscillators signal overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $727 million in 2025, and has achieved positive net income after years of losses, yet maintains a negative shareholder equity position. Recent news highlights strategic AI partnerships and strong quarterly performance.
The outlook is cautiously optimistic, driven by AI-driven demand and enterprise growth, but significant risks persist, including high valuation multiples, negative equity, and intense competition. Analyst consensus is mixed, with a majority Hold rating, suggesting the stock may be fully valued near-term despite operational improvements.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
